PD55-10 IMPACT OF GERMLINE HLA STATUS ON CLINICAL OUTCOMES IN PATIENTS WITH CHEMORESISTANT UROTHELIAL CANCER TREATED WITH PEMBROLIZUMAB

Shintaro Narita,Nobuhiro Fujiyama,Syuhei Takahashi,Takashi Kobayashi,Shingo Hatakeyama,Sei Naito,Renpei Kato,Toru Sakatani,Soki Kashima,Ryohei Yamamoto,Atsushi Koizumi,Taketoshi Nara,Kazuyuki Numakura,Mitsuru Saito,Tomonori Habuchi

PD55-10 IMPACT OF GERMLINE HLA STATUS ON CLINICAL OUTCOMES IN PATIENTS WITH CHEMORESISTANT UROTHELIAL CANCER TREATED WITH PEMBROLIZUMAB

2021

Shintaro Narita
Nobuhiro Fujiyama
Syuhei Takahashi
Takashi Kobayashi
Shingo Hatakeyama
Sei Naito
Renpei Kato
Toru Sakatani
Soki Kashima
Ryohei Yamamoto
Atsushi Koizumi
Taketoshi Nara
Kazuyuki Numakura
Mitsuru Saito
Tomonori Habuchi

INTRODUCTION AND OBJECTIVE:Recent evidence suggests that human leukocyte antigen class I (HLA-I) genotypes influence cancer response to checkpoint blockade immunotherapy. In this study, we assessed...

Keywords:

Oncology
Pembrolizumab
Genotype
Cancer
Medicine
Checkpoint Blockade Immunotherapy
Internal medicine
urothelial cancer
Human leukocyte antigen
Germline
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations